Ge Yunfei, Ding Yinlu, Zhang Jianliang, Li Zhanyuan, Li Zhaoting
Department of General Surgery, The Second Hospital of Shandong University Jinan 250033, China.
Department of General Surgery, Qilu Hospital of Shandong University Jinan 250012, China.
Int J Clin Exp Med. 2014 Oct 15;7(10):3578-82. eCollection 2014.
This study was to investigate inhibiting effect of angiogenesis inhibitor SU6668 in combination with 5-Fu on liver metastasis from human colon cancer. Results showed that metastasis rates in SU6668+5-Fu group, SU6668 group, 5-Fu group decreased obviously (P<0.01). Compared with 5-Fu group and control group, microvessel density significantly decreased in SU6668+5-Fu group and SU6668 group (P<0.05). Vascular endothelial growth factor and base fibroblast growth factor reduced obviously in SU6668+5-Fu group, SU6668 group and 5-Fu group compared with control group, and there were significant differences among SU6668+5-Fu group, SU6668 group and 5-Fu group (P<0.05). Thus, SU6668 can inhibit liver metastasis from colorectal cancer through anti-angiogenesis, and it would have a synergistic effect in combination with 5-Fu. Therefore, SU6668 combined with 5-Fu could be considered as a safe and effective antitumor strategy.
本研究旨在探讨血管生成抑制剂SU6668联合5-氟尿嘧啶对人结肠癌肝转移的抑制作用。结果显示,SU6668+5-氟尿嘧啶组、SU6668组、5-氟尿嘧啶组的转移率明显降低(P<0.01)。与5-氟尿嘧啶组和对照组相比,SU6668+5-氟尿嘧啶组和SU6668组的微血管密度显著降低(P<0.05)。与对照组相比,SU6668+5-氟尿嘧啶组、SU6668组和5-氟尿嘧啶组的血管内皮生长因子和碱性成纤维细胞生长因子明显降低,且SU6668+5-氟尿嘧啶组、SU6668组和5-氟尿嘧啶组之间存在显著差异(P<0.05)。因此,SU6668可通过抗血管生成抑制结直肠癌肝转移,且与5-氟尿嘧啶联合具有协同作用。所以,SU6668联合5-氟尿嘧啶可被视为一种安全有效的抗肿瘤策略。